
	Three Months Ended March 31,
(In Thousands, Except Per Share Amounts)	2026		2025
Basic Earnings/(Loss) per Share:
Net income/(loss) to common stockholders	$	(984)	$	41,176
Dividends declared on preferred stock	(10,424)		(8,219)
Dividends, dividend equivalents and undistributed earnings allocated to participating securities	(318)		(206)
Net income/(loss) attributable to common stockholders - basic	$	(11,726)	$	32,751
Basic weighted average common shares outstanding	104,253		103,777
Basic Earnings/(Loss) per Share	$	(0.11)	$	0.32

Diluted Earnings/(Loss) per Share:
Net income/(loss) to common stockholders - basic	$	(11,726)	$	32,751
Dividends, dividend equivalents and undistributed earnings allocated to participating securities	—		—

Net income/(loss) attributable to common stockholders - diluted	$	(11,726)	$	32,751
Basic weighted average common shares outstanding	104,253		103,777
Unvested and vested restricted stock units	2,044		1,602

Diluted weighted average common shares outstanding (1)	106,297		105,379
Diluted Earnings/(Loss) per Share	$	(0.11)	$	0.31

(1)At March 31, 2026 and 2025, the Company had approximately 1,073,000 and 800,000 equity instruments outstanding that were excluded from the calculation of diluted EPS for the three months ended March 31, 2026 and 2025, as they were determined to be anti-dilutive. These equity instruments reflect RSUs (based on current estimate of expected share settlement amount) with a weighted average grant date fair value of $9.92 and $10.37, respectively. These equity instruments may have a dilutive impact on future EPS.